Aclaris Therapeutics
$1.069876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.02 (+1.92%) As of 1:57 PM EDT today
+$0.02 (+1.92%) Today
Why Robinhood?
You can buy or sell ACRS and other stocks, options, ETFs, and crypto commission-free!
About ACRS
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. Read More The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
Employees
77
Headquarters
Malvern, Pennsylvania
Founded
2012
Market Cap
42.36M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
341.92K
High Today
$1.08
Low Today
$0.9696
Open Price
$1.03
Volume
106.68K
52 Week High
$7.15
52 Week Low
$0.70
Collections
ACRS Earnings
-$1.33
-$0.89
-$0.44
$0.00
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected May 7, After Hours